Active Biotech AB
BTPC
Company Profile
Business description
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
Contact
Scheelevagen 22
P.O. Box 724
Lund223 63
SWET: +46 46192000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Wide moat stock exchange remains cheap
Aussie stock exchange remains materially undervalued despite growing cost concerns.
stocks
ASX data center player expands pipeline but questions remain
Questions surround Australia’s largest data center developer and its growing pipeline.
stocks
Cheap e-commerce share continues sales momentum
The e-commerce business continues its sales momentum despite challenging backdrop.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,965.00 | 77.80 | 0.88% |
| CAC 40 | 8,183.34 | 5.53 | -0.07% |
| DAX 40 | 25,104.70 | 12.45 | 0.05% |
| Dow JONES (US) | 51,032.46 | 363.49 | 0.72% |
| FTSE 100 | 10,409.28 | 16.68 | -0.16% |
| HKSE | 25,182.39 | 176.23 | 0.70% |
| NASDAQ | 26,972.62 | 55.15 | 0.20% |
| Nikkei 225 | 66,329.50 | 1,636.38 | 2.53% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,580.06 | 16.43 | 0.22% |
| S&P/ASX 200 | 8,731.70 | 73.10 | 0.84% |
| SSE Composite Index | 4,068.57 | 30.07 | -0.73% |